The Institute for Clinical and Economic Review (ICER) on Thursday, Nov. 7, released a draft evidence report on acute migraine therapies, including Biohaven's rimegepant, Allergan's ubrogepant and Eli Lilly's lasmiditan. The report is open to public comment until 5 p.m. EST Dec. 6. To read the […]
Latest Stories
SWHR Works to Ensure Frameworks ‘Comprehensively Measure Value’
The Society for Women's Health Research (SWHR) has developed a set of principles it says are necessary to ensure "value frameworks and assessments reflect factors relevant to women and the ongoing improvement of their health." "Value assessments should account for diversity in patients (including […]
Study Finds ‘Significant Variation’ in Evidence-Based Decision Making Among Health Plans
A recent study by the National Pharmaceutical Council (NPC) and Center for the Evaluation and Risk in Health at Tufts Medical Center found "significant variation" in how health plans use evidence in coverage decisions. The study evaluated 1,562 policies from the 17 largest health plans in the […]
Report: Little Momentum Seen in Use of CVS Option that Uses ICER Assessments
CVS Health Corp's top medical executive says a health plan which incorporates assessments by the Institute for Clinical and Economic Review (ICER) has gained little traction, Reuters reports. According to the report, CVS says it has held off on marketing the option amid criticism from patient […]
Frost & Sullivan Honors Inovalon as Company of the Year
Frost & Sullivan on Nov. 5 honored Inovalon with the 2019 North America Company of the Year Award. According to a press release, the company's "technology platform was determined to be highly differentiated in its ability to inform and enable better care, efficiency, and financial performance […]
Report: Data Reveal How ICER Framework Could Hamstring Drug Access
Xcenda in a new analysis suggests that the Institute for Clinical and Economic Review's (ICER) value assessment framework, when incorporated into state Medicaid programs, could actually hamper access to drugs. Xcenda evaluated Medicaid utilization data in California, Massachusetts, Maryland, […]
Mount Sinai Launches New Wellness App
Mount Sinai announced the launch of a new precision wellness app called N1, which was developed at its Icahn School of Medicine. The iPhone app, according to a press release, allows users to answer a host of wellness-related questions in a "statistically rigorous way." "We've taken the tools […]
WSJ Article Takes Deep Dive Into ICER
The Wall Street Journal in a recent article takes a deep dive into the Institute for Clinical and Economic Review (ICER), its methodology and the much-discussed quality-adjusted life year (QALY) metric. ICER has gained influence in the pharmaceutical pricing arena with its drug reports, evidenced […]
Chavez Highlights Challenge of High-Cost Drugs in Value-Based Models
New Mexico Oncology Hematology Consultants CEO Nina Chavez in a recent interview with the American Journal of Managed Care discussed the complexities of high-cost drugs in value-based care models. To watch Chavez's comments on AJMC, click here. […]
White House Taps Hahn to Lead FDA
President Donald Trump has tapped MD Anderson Cancer Center's Dr. Stephen Hahn to head the Food and Drug Administration, according to a BioPharma Dive report. Hahn will replace acting FDA Commissioner Ned Sharpless if he gets the Senate's confirmation. To read the full report on BioPharma […]
